THRD NASDAQ
Third Harmonic Bio, Inc.
1W: +0.0%
1M: -1.3%
3M: +4.3%
1Y: -50.5%
$5.38
Last traded 2025-08-12 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$242.8M
52W Range3.18-16.02
Volume1,416,403
Avg Volume262,783
Beta2.13
Dividend—
Analyst Ratings
Company Info
CEONatalie C. Holles
Employees31
SectorHealthcare
IndustryBiotechnology
IPO Date2022-09-14
Websitethirdharmonicbio.com
300 Technology Square
Cambridge, MA 02139
US
Cambridge, MA 02139
US
617-915-6680
About Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticariaâa skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivityâand is also being explored for its potential in respiratory and digestive tract disorders. Previously known as Project IGE, Inc., the company adopted its current name, Third Harmonic Bio, Inc., in June of 2019. Established in 2019, its corporate headquarters are situated in Cambridge, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Holles Natalie C. | J-Other | 998,854 | — | 2025-08-11 |
| Holles Natalie C. | J-Other | 50,000 | — | 2025-08-11 |
| Holles Natalie C. | J-Other | 1,218,836 | $5.35 | 2025-08-11 |
| Gladstone Michael | J-Other | 43,584 | — | 2025-08-11 |
| Murphy Christopher M | J-Other | 47,500 | — | 2025-08-11 |